Daiichi Sankyo (TSE: 4568) said today that it has chosen for Daiichi Sankyo RD Novare closure (based in Edogawa-ku, Tokyo; hereinafter referred to as “RD Novare”).
Daiichi Sankyo plans to further integrate RD Novare’s services into its own organisation in order to boost its R&D capabilities.
RD Novare History:
Daiichi Sankyo RD Associe Co., Ltd. was created in 2006 as RD Novare to support Daiichi Sankyo’s drug discovery and clinical development. The corporate name was changed to the current one in 2011. RD Novare, which has cutting-edge research technology infrastructure and a strong clinical development capabilities, contributes to the R&D of the Daiichi Sankyo group of enterprises by helping to produce novel drugs.
Expected date to dissolve the corporate entity
RD Novare will cease operations as a corporate entity on March 31, 2024.
Rationale behind RD Novare Closure:
Daiichi Sankyo will merge R&D strengths within the Daiichi Sankyo group of companies, resulting in the development and implementation of a consistent research strategy for drug discovery, rapid decision-making, and the strengthening of global clinical development for the 5DXd-ADCs, including ENHERTU®.
About Daiichi Sankyo:
Daiichi Sankyo is a forward-thinking global healthcare firm that finds, develops, and delivers new standards of care to improve people’s quality of life around the world. Daiichi Sankyo, with over 120 years of expertise, uses world-class science and technology to develop novel modalities and revolutionary medications for individuals suffering from cancer, cardiovascular disease, and other diseases with high unmet medical need.
